Role of hypoxia-inducible factor-1α in pathogenesis and disease evaluation of ulcerative colitis

Xu,Chunmei; Dong,Weiguo

doi:10.3892/etm.2016.3030

Role of hypoxia-inducible factor-1α in pathogenesis and disease evaluation of ulcerative colitis

Authors:
- Chunmei Xu
- Weiguo Dong
View Affiliations

Affiliations: Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: January 28, 2016 https://doi.org/10.3892/etm.2016.3030
Pages: 1330-1334
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The main aim of the present study was to measure hypoxia-inducible factor‑1α (HIF‑1α) in serum and colonic mucosa of ulcerative colitis (UC) patients and to analyze its role in the pathogenesis, disease activity and severity of UC. A total of 47 UC patients and 13 UC in remission patients were recruited for the present study. Ten healthy subjects were also included to serve as controls. HIF‑1α in the serum was measured using ELISA. The citrate‑microwave‑SP immunohistochemical method was used to measure the expression of HIF‑1α in colonic mucosa. The results showed that, HIF‑1α in serum was notably higher in UC patients (73.21±28.65) than UC in remission patients (44.54±14.75) and controls (42.83±15.49). The difference between UC patients and UC in remission patients was significant (P<0.05). A correlation analysis revealed that, the HIF‑1α level in serum was positively associated with disease activity, disease severity and endoscopic grade. The expression of HIF‑1α in colonic mucosa of UC patients was (58.05±13.83) higher than that in UC in remission patients (3.00±2.72) and controls (3.04±2.69) and this difference was statistically significant (P<0.05). A positive correlation was identified between the expression of HIF‑1α in colonic mucosa and the disease activity, severity and endoscopic grade. Thus, the present findings indicated that, HIF‑1α is likely to play an important role in the pathogenesis of UC and may serve as a biomarker to evaluate disease activity and severity in UC patients.

View Figures

View References

1	Diamanti A, Knafelz D, Panetta F, De Angelis P, Candusso M, Bracci F, Papadatou B, Francalanci P, Monti L and Torre G: Thalidomide as rescue therapy for acute severe ulcerative colitis. Eur Rev Med Pharmacol Sci. 18:1690–1693. 2014.PubMed/NCBI
2	Hu D, Xia SL, Shao XX, Yu LQ, Lin XX, Guo M, Lin XQ and Jiang Y: Association of ulcerative colitis with TNF-related apoptosis inducing ligand (TRAIL) gene polymorphisms and plasma soluble TRAIL levels in Chinese Han population. Eur Rev Med Pharmacol Sci. 19:467–476. 2015.PubMed/NCBI
3	Dong WG, Liu SP, Yu BP, Wu DF, Luo HS and Yu JP: Ameliorative effects of sodium ferulate on experimental colitis and their mechanisms in rats. World J Gastroenterol. 9:2533–2538. 2003.PubMed/NCBI
4	Pica R, Cassieri C, Pronio AM, Zippi M, Avallone EV, Montesani C, Occhigrossi G and Paoluzi P: Quality of life in ulcerative colitis patients treated medically versus patients undergoing surgery. Eur Rev Med Pharmacol Sci. 18:693–698. 2014.PubMed/NCBI
5	Bai R, Zhao AQ, Zhao ZQ, Liu WL and Jian DM: MicroRNA-195 induced apoptosis in hypoxic chondrocytes by targeting hypoxia-inducible factor 1 alpha. Eur Rev Med Pharmacol Sci. 19:545–551. 2015.PubMed/NCBI
6	Wei H, Li F, Fu P and Liu X: Effects of the silencing of hypoxia-inducible factor-1 alpha on metastasis of pancreatic cancer. Eur Rev Med Pharmacol Sci. 17:436–446. 2013.PubMed/NCBI
7	Zhang M, Gao X, Bai SJ, Ye XM and Zhang J: Effect of pioglitazone on expression of hypoxia-inducible factor 1α and vascular endothelial growth factor in ischemic hindlimb of diabetic rats. Eur Rev Med Pharmacol Sci. 18:1307–1314. 2014.PubMed/NCBI
8	Semenza GL and Wang GL: A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Bio. 12:5447–5454. 1992. View Article : Google Scholar
9	Maxwell PH, Pugh CW and Ratcliffe PJ: Activation of the HIF pathway in cancer. Curr Opin Genet Dev. 11:293–299. 2001. View Article : Google Scholar : PubMed/NCBI
10	Thornton RD, Lane P, Borghaei Re, et al: Interleukin 1 induceshypoxia-inducible factor 1 in human gingival and synovialfibroblasts. Biochem J. 350:307–312. 2000. View Article : Google Scholar : PubMed/NCBI
11	Albina JE, Mastrofrancesco B, Vessella JA, et al: HIF-1 expression in healing wounds: HIF-1alpha induction in primary inflammatory cells by TNF-alpha. Am J Physiol Cell Physiol. 281:1971–1977. 2001.
12	Ouyang Q, Hu PJ, Qian JM, Zheng JJ and Hu RW: Consensus on the management of inflammatory bowel disease in China in 2007. J Dig Dis. 8:545–561. 2007.
13	Urgesi R, Zampaletta C, Masini A, Pelecca G, Pastorelli A, De Lorenzo A and Faggiani R: Spontaneous right ventricular thrombus in a patient with active ulcerative colitis and protein C deficiency: a review with a case report. Eur Rev Med Pharmacol Sci. 14:455–463. 2010.PubMed/NCBI
14	Federico A, Tuccillo C, Grossi E, Abbiati R, Garbagna N, Romano M, Tiso A, del Blanco CV and Loguercio C: The effect of a new symbiotic formulation on plasma levels and peripheral blood mononuclear cell expression of some pro-inflammatory cytokines in patients with ulcerative colitis: a pilot study. Eur Rev Med Pharmacol Sci. 13:285–293. 2009.PubMed/NCBI
15	Blanco MI, Becerra M, González-Siso MI and Cerdán ME: Functional characterization of KlHEM13, a hypoxic gene of Kluyveromyces lactis. Can J Microbiol. 51:241–249. 2005. View Article : Google Scholar : PubMed/NCBI
16	Le QT, Denko NC and Giaccia AJ: Hypoxic gene expression and metastasis. Cancer Metastasis Rev. 23:293–310. 2004. View Article : Google Scholar : PubMed/NCBI
17	Sanges M, Valente G, Rea M, Della Gatta R, De Franchis G, Sollazzo R and D'Arienzo A: Probiotics in spondyloarthropathy associated with ulcerative colitis: a pilot study. Eur Rev Med Pharmacol Sci. 13:233–234. 2009.PubMed/NCBI
18	Schmidt C, Lautenschläger C, Petzold B, Sakr Y, Marx G and Stallmach A: Confocal laser endomicroscopy reliably detects sepsis-related and treatment-associated changes in intestinal mucosal microcirculation. Br J Anaesth. 111:996–1003. 2013. View Article : Google Scholar : PubMed/NCBI
19	Harrois A, Baudry N, Huet O, Kato H, Lohez M, Ziol M, Duranteau J and Vicaut E: Synergistic deleterious effect of hypoxemia and hypovolemia on microcirculation in intestinal villi. Crit Care Med. 41:e376–e384. 2013. View Article : Google Scholar : PubMed/NCBI
20	Lehmann Ch, Abdo I, Kern H, Maddison L, Pavlovic D, Sharawi N, Starkopf J, Hall R, Johnson P, Williams L, et al: MiDAS (Microcirculation Diagnostics and Applied Studies) group: Clinical evaluation of the intestinal microcirculation using sidestream dark field imaging - recommendations of a round table meeting. Clin Hemorheol Microcirc. 57:137–146. 2014.PubMed/NCBI
21	Yeh YC, Sun WZ, Ko WJ, Chan WS, Fan SZ, Tsai JC and Lin TY: Dexmedetomidine prevents alterations of intestinal microcirculation that are induced by surgical stress and pain in a novel rat model. Anesth Analg. 115:46–53. 2012. View Article : Google Scholar : PubMed/NCBI
22	Armuzzi A, De Pascalis B, Lupascu A, Fedeli P, Leo D, Mentella MC, Vincenti F, Melina D, Gasbarrini G, Pola P, et al: Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci. 8:231–233. 2004.PubMed/NCBI
23	Giatromanolaki A, Sivridis E, Maltezos E, Papazoglou D, Simopoulos C, Gatter KC, Harris AL and Koukourakis MI: Hypoxia inducible factor 1alpha and 2alpha overexpression in inflammatory bowel disease. J Clin Pathol. 56:209–213. 2003. View Article : Google Scholar : PubMed/NCBI
24	Jeong HJ, Chung HS, Lee BR, Kim SJ, Yoo SJ, Hong SH and Kim HM: Expression of proinflammatory cytokines via HIF-1alpha and NF-kappaB activation on desferrioxamine-stimulated HMC-1 cells. Biochem Biophys Res Commun. 306:805–811. 2003. View Article : Google Scholar : PubMed/NCBI
25	Xu CM, Dong WG, Yu BP, et al: Expression of hypoxia-inducible factor-1α and inflammation-induced enzyme in inflammatory bowel disease. J Clinical Gastroente. 17:103–105. 2005.
26	Cramer T, Yamanishi Y, Clausen BE, Förster I, Pawlinski R, Mackman N, Haase VH, Jaenisch R, Corr M, Nizet V, et al: HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell. 112:645–657. 2003. View Article : Google Scholar : PubMed/NCBI
27	Hu F, Liu H, Xu L, et al: Hypoxia-inducible factor-1α perpetuates synovial fibroblast interactions with T cells and B cells in rheumatoid arthritis. Eur J Immunol. November 25–2015.(Epub ahead of print). doi: 10.1002/eji.201545784. View Article : Google Scholar : PubMed/NCBI
28	Zhang X, Liu J, Wan L, et al: Up-regulated expressions of HIF-1α, VEGF and CD34 promote synovial angiogenesis in rats with adjuvant arthritis. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 31:1053–1056. 2015.PubMed/NCBI
29	Lee SH, Lee SH, Kim CH, et al: Increased expression of vascular endothelial growth factor and hypoxia inducible factor-1α in lung tissue of patients with chronic bronchitis. Clin Biochem. 47:552–559. 2014. View Article : Google Scholar : PubMed/NCBI
30	Tao H, Luo W, Pei H, Zhu S, Zhang M, Chen B, He J, Zhang M and Zhou R: Expression and significance of hypoxia-inducible factor-1α in patients withchronic obstructive pulmonary disease and smokers with normal lung function. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 30:852–855. 2014.PubMed/NCBI
31	Liu JB, Ding JQ and Wang L: Immunohistochemical study of dental pulp inflammation of hypoxia-inducible factor-1α. J Clin Stomatol. 19:77–78. 2003.
32	Hellwig-Bürgel T, Rutkowski K, Metzen E, Fandrey J and Jelkmann W: Interleukin-1beta and tumor necrosis factor-alpha stimulate DNA binding of hypoxia-inducible factor-1. Blood. 94:1561–1567. 1999.PubMed/NCBI
33	Wang BL and Wang XR: Regulation of hypoxia inducible factor-1α by the inflammatory mediators. Int J Pathol Clin Med. 90:1673–2588. 2008.
34	Ngo DT, Farb MG, Kikuchi R, Karki S, Tiwari S, Bigornia SJ, Bates DO, LaValley MP, Hamburg NM, Vita JA, et al: Antiangiogenic actions of vascular endothelial growth factor-A165b, an inhibitory isoform of vascular endothelial growth factor-A, in human obesity. Circulation. 130:1072–1080. 2014. View Article : Google Scholar : PubMed/NCBI
35	Cătană CS, Neagoe Berindan I, Cozma V, Magdaş C, Tăbăran F and Dumitraşcu DL: Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease. World J Gastroenterol. 21:5823–5830. 2015.PubMed/NCBI
36	Avallone EV, Pica R, Cassieri C, Zippi M, Paoluzi P and Vernia P: Azathioprine treatment in inflammatory bowel disease patients: type and time of onset of side effects. Eur Rev Med Pharmacol Sci. 18:165–170. 2014.PubMed/NCBI